Literature DB >> 5640790

Hematological recovery in the mouse following single doses of gamma radiation and cyclophosphamide.

F A Valeriote, D C Collins, W R Bruce.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5640790

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


× No keyword cloud information.
  9 in total

Review 1.  An assessment of massive-dose chemotherapy of malignant disease.

Authors:  D E Bergsagel
Journal:  Can Med Assoc J       Date:  1971-01-09       Impact factor: 8.262

2.  [Cytogenetic changes in white blood cells after cyclophosphamide treatment].

Authors:  M Bauchinger; E Schmid
Journal:  Z Krebsforsch       Date:  1969

3.  Tolerance of hemopoiesis for repeated cytotoxic drug therapy.

Authors:  H P Lohrmann
Journal:  Blut       Date:  1979-10

4.  Increase in the survival time of mice exposed to ionizing radiation by a new class of free radical scavengers.

Authors:  P Buc-Calderon; M Roberfroid
Journal:  Experientia       Date:  1990-07-15

5.  Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.

Authors:  M R Nowrousian; C G Schmidt
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

6.  Delayed toxicity of cyclophosphamide in normal mice.

Authors:  E Anton
Journal:  Br J Exp Pathol       Date:  1987-04

7.  Protection of bone marrow progenitor cells by superoxide dismutase.

Authors:  A Petkau
Journal:  Mol Cell Biochem       Date:  1988-12       Impact factor: 3.396

8.  Effects of cisplatin on different haemopoietic progenitor cells in mice.

Authors:  M R Nowrousian; C G Schmidt
Journal:  Br J Cancer       Date:  1982-09       Impact factor: 7.640

9.  Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain.

Authors:  D J Honess; N M Bleehen
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.